Literature DB >> 30126960

Contributions of yap1 Mutation and Subsequent atrF Upregulation to Voriconazole Resistance in Aspergillus flavus.

Yuuta Ukai1, Miho Kuroiwa2, Naoko Kurihara2, Hiroki Naruse2, Tomoyuki Homma2, Hideki Maki2, Akira Naito2.   

Abstract

Aspergillus flavus is the second most significant pathogenic cause of invasive aspergillosis; however, its emergence risks and mechanisms of voriconazole (VRC) resistance have not yet been elucidated in detail. Here, we demonstrate that repeated exposure of A. flavus to subinhibitory concentrations of VRC in vitro causes the emergence of a VRC-resistant mutant with a novel resistance mechanism. The VRC-resistant mutant shows a MIC of 16 μg/ml for VRC and of 0.5 μg/ml for itraconazole (ITC). Whole-genome sequencing analysis showed that the mutant possesses a point mutation in yap1, which encodes a bZIP transcription factor working as the master regulator of the oxidative stress response, but no mutations in the cyp51 genes. This point mutation in yap1 caused alteration of Leu558 to Trp (Yap1Leu558Trp) in the putative nuclear export sequence in the carboxy-terminal cysteine-rich domain of Yap1. This Yap1Leu558Trp substitution was confirmed as being responsible for the VRC-resistant phenotype, but not for that of ITC, by the revertant to Yap1wild type with homologous gene replacement. Furthermore, Yap1Leu558Trp caused marked upregulation of the atrF ATP-binding cassette transporter, and the deletion of atrF restored susceptibility to VRC in A. flavus These findings provide new insights into VRC resistance mechanisms via a transcriptional factor mutation that is independent of the cyp51 gene mutation in A. flavus.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Aspergillus flavus; atrF; azole resistance; voriconazole; yap1

Mesh:

Substances:

Year:  2018        PMID: 30126960      PMCID: PMC6201102          DOI: 10.1128/AAC.01216-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  64 in total

Review 1.  Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature.

Authors:  Simone M T Camps; Jan W M van der Linden; Yi Li; Ed J Kuijper; Jaap T van Dissel; Paul E Verweij; Willem J G Melchers
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

2.  Contributions of Aspergillus fumigatus ATP-binding cassette transporter proteins to drug resistance and virulence.

Authors:  Sanjoy Paul; Daniel Diekema; W Scott Moye-Rowley
Journal:  Eukaryot Cell       Date:  2013-10-11

3.  Induction of Mitochondrial Reactive Oxygen Species Production by Itraconazole, Terbinafine, and Amphotericin B as a Mode of Action against Aspergillus fumigatus.

Authors:  Elena Shekhova; Olaf Kniemeyer; Axel A Brakhage
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

4.  Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry.

Authors:  William J Steinbach; Kieren A Marr; Elias J Anaissie; Nkechi Azie; Shun-Ping Quan; Herwig-Ulf Meier-Kriesche; Senu Apewokin; David L Horn
Journal:  J Infect       Date:  2012-08-13       Impact factor: 6.072

5.  Genotype-phenotype complexity of the TR46/Y121F/T289A cyp51A azole resistance mechanism in Aspergillus fumigatus.

Authors:  Eveline Snelders; Simone M T Camps; Anna Karawajczyk; Antonius J M M Rijs; Jan Zoll; Paul E Verweij; Willem J G Melchers
Journal:  Fungal Genet Biol       Date:  2015-06-16       Impact factor: 3.495

6.  The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus.

Authors:  Marcin G Fraczek; Michael Bromley; Ahmed Buied; Caroline B Moore; Ranjith Rajendran; Riina Rautemaa; Gordon Ramage; David W Denning; Paul Bowyer
Journal:  J Antimicrob Chemother       Date:  2013-04-10       Impact factor: 5.790

7.  Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase.

Authors:  Paul A Mann; Raulo M Parmegiani; Shui-Qing Wei; Cara A Mendrick; Xin Li; David Loebenberg; Beth DiDomenico; Roberta S Hare; Scott S Walker; Paul M McNicholas
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

8.  Molecular characterisation of cyp51A and cyp51B genes coding for P450 14alpha-lanosterol demethylases A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus.

Authors:  Suganthini Krishnan-Natesan; Pranatharthi H Chandrasekar; George J Alangaden; Elias K Manavathu
Journal:  Int J Antimicrob Agents       Date:  2008-09-04       Impact factor: 5.283

9.  A Novel Zn2-Cys6 Transcription Factor AtrR Plays a Key Role in an Azole Resistance Mechanism of Aspergillus fumigatus by Co-regulating cyp51A and cdr1B Expressions.

Authors:  Daisuke Hagiwara; Daisuke Miura; Kiminori Shimizu; Sanjoy Paul; Ayumi Ohba; Tohru Gonoi; Akira Watanabe; Katsuhiko Kamei; Takahiro Shintani; W Scott Moye-Rowley; Susumu Kawamoto; Katsuya Gomi
Journal:  PLoS Pathog       Date:  2017-01-04       Impact factor: 6.823

10.  Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure.

Authors:  Susan J Howard; Dasa Cerar; Michael J Anderson; Ahmed Albarrag; Matthew C Fisher; Alessandro C Pasqualotto; Michel Laverdiere; Maiken C Arendrup; David S Perlin; David W Denning
Journal:  Emerg Infect Dis       Date:  2009-07       Impact factor: 6.883

View more
  8 in total

Review 1.  Aspergillus fumigatus and aspergillosis: From basics to clinics.

Authors:  A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl
Journal:  Stud Mycol       Date:  2021-05-10       Impact factor: 16.097

Review 2.  Oxidative stress response pathways in fungi.

Authors:  Hajar Yaakoub; Sara Mina; Alphonse Calenda; Jean-Philippe Bouchara; Nicolas Papon
Journal:  Cell Mol Life Sci       Date:  2022-06-01       Impact factor: 9.261

Review 3.  Invasive Aspergillosis by Aspergillus flavus: Epidemiology, Diagnosis, Antifungal Resistance, and Management.

Authors:  Shivaprakash M Rudramurthy; Raees A Paul; Arunaloke Chakrabarti; Johan W Mouton; Jacques F Meis
Journal:  J Fungi (Basel)       Date:  2019-07-01

4.  The high efficacy of luliconazole against environmental and otomycosis Aspergillus flavus strains.

Authors:  Maryam Moslem; Ali Zarei Mahmoudabadi
Journal:  Iran J Microbiol       Date:  2020-04

5.  The bZIP Transcription Factor AflRsmA Regulates Aflatoxin B1 Biosynthesis, Oxidative Stress Response and Sclerotium Formation in Aspergillus flavus.

Authors:  Xinua Wang; Wenjie Zha; Linlin Liang; Opemipo Esther Fasoyin; Lihan Wu; Shihua Wang
Journal:  Toxins (Basel)       Date:  2020-04-23       Impact factor: 4.546

Review 6.  Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium.

Authors:  Amir Arastehfar; Toni Gabaldón; Rocio Garcia-Rubio; Jeffrey D Jenks; Martin Hoenigl; Helmut J F Salzer; Macit Ilkit; Cornelia Lass-Flörl; David S Perlin
Journal:  Antibiotics (Basel)       Date:  2020-12-08

7.  Dissection of the Activity of Agricultural Fungicides against Clinical Aspergillus Isolates with and without Environmentally and Medically Induced Azole Resistance.

Authors:  Karin Meinike Jørgensen; Marie Helleberg; Rasmus Krøger Hare; Lise Nistrup Jørgensen; Maiken Cavling Arendrup
Journal:  J Fungi (Basel)       Date:  2021-03-11

Review 8.  The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.

Authors:  Martin Hoenigl; Rosanne Sprute; Matthias Egger; Amir Arastehfar; Oliver A Cornely; Robert Krause; Cornelia Lass-Flörl; Juergen Prattes; Andrej Spec; George R Thompson; Nathan Wiederhold; Jeffrey D Jenks
Journal:  Drugs       Date:  2021-10-09       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.